Skip to main content

Meeting Highlights

Meeting Highlights

ASH Highlights, Leukemia

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Meeting Highlights

ASH Highlights, Leukemia

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

Meeting Highlights

ASH Highlights, Leukemia

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Meeting Highlights

ASH Highlights, Lymphoma

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

ASH Highlights, Immunotherapy, Lymphoma

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Meeting Highlights

ASH Highlights, Myelofibrosis

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Meeting Highlights

ESMO Highlights

Ceritinib Effective in Treating Brain Metastases in NSCLC

Meeting Highlights

ESMO Highlights, PARP Inhibitors

Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer

3
4
5
6
7
8

Page 6 of 8
Results 51 - 60 of 72